Story perspectives

FDA-Approved Drug May Prevent Alzheimer's Toxic Peptides

2/12/2026

Summary

Story summary

Northwestern University researchers report that the FDA-approved anti-seizure drug levetiracetam can prevent production of toxic amyloid-beta 42 peptides linked to Alzheimer's disease.
The study, published in Science Translational Medicine, shows levetiracetam modifies the synaptic vesicle cycle and keeps amyloid precursor protein on the neuron surface.
This mechanism suggests a preventive approach by reducing harmful peptide production.
The study also analyzed brain tissue from Down syndrome patients, reinforcing preventive potential.

1 of 1

Story summary

Northwestern University researchers report that the FDA-approved anti-seizure drug levetiracetam can prevent production of toxic amyloid-beta 42 peptides linked to Alzheimer's disease.
The study, published in Science Translational Medicine, shows levetiracetam modifies the synaptic vesicle cycle and keeps amyloid precursor protein on the neuron surface.
This mechanism suggests a preventive approach by reducing harmful peptide production.
The study also analyzed brain tissue from Down syndrome patients, reinforcing preventive potential.